Foundation as Manufacturer Commercialization Platform

This pushes Foundation up the value chain from clinic software into drug commercialization infrastructure. A manufacturer program is not just a branded telehealth flow, it is a way for a drug company to own the patient intake, prescription routing, refill behavior, and adherence data that would otherwise sit with PBMs, pharmacies, or a consumer telehealth brand. Foundation fits because it already bundles the pieces needed to run that loop, telehealth, pharmacy, diagnostics, and automated follow up.

• The clearest proof point is obesity drugs. LillyDirect created a manufacturer controlled access path, and partners like HealthTap, Noom, Ro, and LifeMD plugged telehealth and fulfillment into that path. That shows large drug companies now want software and care delivery partners, not just wholesalers and PBMs.
  2 sacra 5 sacra 6 sacra
• For Foundation, manufacturer programs are higher value than basic white label clinics because the customer is buying revenue retention and patient visibility. The workflow starts with branded intake, moves through prescribing and fulfillment, then keeps patients engaged with refill reminders, prior authorization handling, and adherence monitoring.
  1 sacra
• Ro is the closest comparable for what this becomes at scale. Its platform is already being used both to distribute branded GLP-1s through manufacturer channels and to generate de identified access data for companies like Amgen. That is the broader prize, not just script volume, but real world demand and coverage intelligence.
  6 sacra

The next step is more drug makers treating virtual care and fulfillment as part of launch strategy, especially in categories with cash pay demand, access friction, and long treatment duration. If Foundation becomes the default back end for these programs, it can turn each manufacturer relationship into recurring infrastructure revenue and a stronger position inside the drug distribution stack.